Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB

Alligator Bioscience AB (publ) today announces that Tova Landström, PhD, Medical Science Director at Alligator, has been appointed as employee representative, and Anette Sundstedt, PhD, Principal Scientist at Alligator, as deputy employee representative at the Alligator Bioscience AB’s Board of Directors, effective March 9, 2023.

Tova Landström, who joined Alligator in 2021, replaces Laura von Schantz, who resigned on February 14, 2023, following her appointment to CTO and member of the Executive Management Team.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Categorized as